Skip to main content
← All trials
Crohn DiseaseGut healthDrugPhase 3

What this study is

The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

What's being tested

  • Guselkumab

    Intervention · DRUG

    Guselkumab will be administered.

  • Risankizumab

    Intervention · DRUG

    Risankizumab will be administered.

Study details

Official title
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab Versus Risankizumab in the Treatment of Participants With Moderately to Severely Active Crohn's Disease
Sponsor
Janssen Research & Development, LLC
Conditions
Crohn Disease
Enrolling
530 people
Starts
2026-04-21
Est. completion
2030-12-11
Design
Open-label, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗